Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma.
暂无分享,去创建一个
R. D. De Abreu | C. Hulsbergen-van de Kaa | M. Ligtenberg | L. P. Van den Heuvel | Lambert H J Lambooy | J. Bökkerink | C. Gidding | C. Hulsbergen–van de Kaa | L. Lambooy
[1] Thomas D. Schmittgen,et al. Real-Time Quantitative PCR , 2002 .
[2] N. Cheung,et al. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] R. Seeger,et al. Detection of minimal residual disease in bone marrow during or after therapy as a prognostic marker for high-risk neuroblastoma. , 2001, Journal of pediatric hematology/oncology.
[4] K. Horibe,et al. Disease Outcome May Be Predicted by Molecular Detection of Minimal Residual Disease in Bone Marrow in Advanced Neuroblastoma: A Pilot Study , 2001, Journal of pediatric hematology/oncology.
[5] 生野 久美子. Clinical Implications of Minimal Disease in the Bone Marrow and Peripheral Blood in Neuroblastoma , 2001 .
[6] K. Matsumoto,et al. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma. , 2001, Medical and pediatric oncology.
[7] C. R. Pinkerton,et al. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. , 2001, Medical and pediatric oncology.
[8] W. London,et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Y. Fujii,et al. Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma. , 2000, Journal of pediatric surgery.
[10] A. Tischler. Divergent differentiation in neuroendocrine tumors of the adrenal gland. , 2000, Seminars in diagnostic pathology.
[11] S. Burchill,et al. Molecular detection of low‐level disease in patients with cancer , 2000, The Journal of pathology.
[12] G. Tonini,et al. Real-time quantitative PCR for the measurement of MYCN amplification in human neuroblastoma with the TaqMan detection system. , 1999, Clinical chemistry.
[13] M. Haber,et al. Use of tumor-specific gene expression for the differential diagnosis of neuroblastoma from other pediatric small round-cell malignancies. , 1999, The American journal of pathology.
[14] S. Burchill,et al. Reverse Transcriptase Polymerase Chain Reaction Cell Lines and Preparation of Cell Spikes Improved Methods Using the Reverse Transcriptase Polymerase Chain Reaction to Detect Tumour Cells , 2022 .
[15] B. Bernardi,et al. High-sensitivity immunocytologic analysis of neuroblastoma cells in paired blood and marrow samples. , 1998, Journal of hematotherapy.
[16] E. Yunis,et al. Detection of Neuroblastoma in the Bone Marrow: Biopsy Versus Aspiration , 1998, Journal of pediatric hematology/oncology.
[17] J. Stéphan,et al. Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection. , 1998, Medical and pediatric oncology.
[18] G. Seitz,et al. Detection of neuroblastoma cells in CD34+ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry. , 1997, European journal of cancer.
[19] K. Sano,et al. Detection of low numbers of neuroblastoma cells in vitro. , 1997, Annals of the Academy of Medicine, Singapore.
[20] S. Mizutani,et al. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction. , 1997, Journal of pediatric surgery.
[21] C. Heid,et al. A novel method for real time quantitative RT-PCR. , 1996, Genome research.
[22] U. Keilholz. Diagnostic PCR in melanoma, methods and quality assurance. Epalinges, Switzerland, 26/27 January 1996 , 1996 .
[23] K. Horibe,et al. Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription‐polymerase chain reaction for tyrosine hydroxylase mRNA , 1996, Cancer.
[24] S. Burchill,et al. Early clinical evaluation of neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction (RT-PCR) for tyrosine hydroxylase mRNA. , 1995, European journal of cancer.
[25] F. Berthold,et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.
[26] A. Evans,et al. Bone marrow transplantation for high risk neuroblastoma at the Children's Hospital of Philadelphia: an update. , 1994, Medical and pediatric oncology.
[27] T. Klingebiel,et al. Peripheral stem cell transplantation in neuroblastoma stage 4 with the use of [131I-m]IBG. , 1994, Progress in clinical and biological research.
[28] R. Abramson,et al. Detection of specific polymerase chain reaction product by utilizing the 5'----3' exonuclease activity of Thermus aquaticus DNA polymerase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[29] R. Seeger,et al. Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. , 1991, Pediatric clinics of North America.
[30] H. Sather,et al. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. , 1991, The New England journal of medicine.
[31] B. Bostrom,et al. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. , 1990, Blood.
[32] J. Zucker,et al. High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: an unselected group of stage IV patients over 1 year of age. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] Adolph E. Christ,et al. Childhood cancer , 2020, The Downstate Series of Research in Psychiatry and Psychology.